Vor Biopharma (VOR) Free Cash Flow (2020 - 2026)
Vor Biopharma (VOR) reported Free Cash Flow of -$38.3 million for Q1 2026, down 23.15% year-over-year from -$49.8 million in Q1 2025, and down 61.34% quarter-over-quarter from -$23.7 million in Q4 2025.
Vor Biopharma (VOR) Free Cash Flow (2020 - 2026) Analysis & Trends
Vor Biopharma (VOR) has 7 years of Free Cash Flow data on file, last reported at -$38.3 million in Q1 2026.
- Free Cash Flow for Q1 2026 came in at -$38.3 million, down 23.15% year-over-year; the trailing twelve-month figure through Mar 2026 was -$150.8 million (down 50.28% YoY), and the FY2025 annual result was -$143.7 million, down 43.81% from the prior year.
- Free Cash Flow declined to -$38.3 million in Q1 2026 per VOR's latest filing, from -$23.7 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$17.6 million in Q3 2022 and troughed at -$53.3 million in Q3 2025.
- A 5-year average of -$27.5 million and a median of -$24.3 million in 2023 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2024 and 2025: Free Cash Flow increased 15.1% in 2024, then plunged 128.6% in 2025.
- A 5-year view of Free Cash Flow shows it stood at -$18.3 million in 2022, then sank by 31.13% to -$24.0 million in 2023, then retreated by 0.42% to -$24.1 million in 2024, then advanced by 1.75% to -$23.7 million in 2025, then tumbled by 61.34% to -$38.3 million in 2026.
- Business Quant data shows VOR's Free Cash Flow at -$38.3 million in Q1 2026, -$23.7 million in Q4 2025, and -$53.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 63,220.27 |
| 10 | Vor Biopharma | 627.54 Mn | 627.54 Mn | - | -38.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -38.26 Mn |
| Mar 31, 2026 | -38.26 Mn |
| Dec 31, 2025 | -23.71 Mn |
| Dec 31, 2025 | -23.71 Mn |
| Sep 30, 2025 | -53.31 Mn |
| Sep 30, 2025 | -53.31 Mn |
| Jun 30, 2025 | -35.57 Mn |
| Jun 30, 2025 | -35.57 Mn |
| Mar 31, 2025 | -31.07 Mn |
| Mar 31, 2025 | -31.07 Mn |
| Dec 31, 2024 | -24.14 Mn |
| Dec 31, 2024 | -24.14 Mn |
| Sep 30, 2024 | -23.32 Mn |
| Sep 30, 2024 | -23.32 Mn |
| Jun 30, 2024 | -21.86 Mn |
| Jun 30, 2024 | -21.86 Mn |
| Mar 31, 2024 | -30.58 Mn |
| Mar 31, 2024 | -30.58 Mn |
| Dec 31, 2023 | -24.03 Mn |
| Dec 31, 2023 | -24.03 Mn |